Efficacy of the Novel Anxiolytic Pregabalin in Social Anxiety Disorder: A Placebo-Controlled, Multicenter Study

Journal of Clinical Psychopharmacology

Volumn 24, Issue 2, 2004, Pages 141-149

  Pande, Atul C ^a,i   Feltner, Douglas E ^a   Jefferson, James W ^b   Davidson, Jonathan R T ^c   Pollack, Mark ^d   Stein, Murray B ^e   Lydiard, R Bruce ^f   Futterer, Rïse ^g   Robinson, Paula ^a   Slomkowski, Mary ^a   DuBoff, Eugene ^h   Phelps, Mary ^a   Janney, Carol A ^a   Werth, John L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Madison Institute of Medicine   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g Dean Found Hlth   (United States)

^h Denver VHA Medical Center   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; PREGABALIN;

ADULT; AGED; AMBLYOPIA; AMNESIA; ANORGASMIA; ARTICLE; ASTHENIA; ATAXIA; AVOIDANCE BEHAVIOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPERSONALIZATION; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEAR; FEMALE; HEADACHE; HUMAN; INFECTION; INTOXICATION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PAIN; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SOCIAL BEHAVIOR DISORDERS; WEIGHT GAIN;

EID: 12144285831     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000117423.05703.e7     Document Type: Article

References (34)

1. Liebowitz MR, Heimberg RG, Fresco DM, et al. Social phobia or social anxiety disorder: what's in a name? [letter]. Arch Gen Psychiatry. 2000; 57:191-192.
2. Schneier FR, Johnson J, Hornig CD, et al. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992; 49:282-288.
3. Jefferson JW. Social phobia: everyone's disorder? J Clin Psychiatry. 1996;57(suppl 6):28-32.
4. Stein MB. Neurobiological perspectives on social phobia: from affiliation to zoology. Biol Psychiatry. 1998;44:1277-1285.
5. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423-428.
6. Connor KM, Davidson JR, Potts NLS, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol. 1998;18:373-378.
7. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Pyschopharmacol. 1999;19:341-348.
8. Taylor CP, Vartanian MG, Andruszkiewiez R, et al. 3-Alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res. 1992;11:103-110.
9. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. 1999;34:1-41.
10. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000;295:1086-1093.
11. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000;280:107-110.
12. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain. 2001;93:191-196.
13. Fehrenbacher Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105:133-141.
14. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2 subunit of a calcium channel. J Biol Chem. 1996;271:5768-5776.
15. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229-236.
16. Kinsora JJ Jr, Serpa KA, Snyder BJ, et al. Anxiolytic-like effects of pregabalin. Abstr Soc Neurosci. 1999;25:1319.
17. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708-713.
18. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987; 22:141-173.
19. Liebowitz MR. Pharmacotherapy of social phobia. J Clin Psychiatry. 1993;54(suppl):31-35.
20. Davidson JR, Potts NLS, Richichi EA, et al. The Brief Social Phobia Scale. J Clin Psychiatry. 1991;52(suppl):48-51.
21. Marks I, Mathews A. Brief standard self-rating for phobia patients. Behav Res Ther. 1979;17:263-267.
22. Connor KM, Davidson JRT, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry. 2000;176:379-386.
23. Hamilton MW. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-60.
24. Hamilton MW. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:1016.
25. Ware JE Jr, Snow KK, Kosinski M, et al. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
26. Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Summary Scales: A User's Manual. Boston: The Health Institute, New England Medical Center; 1994.
27. Steel R, Torrie J. Principles and Procedures of Statistics. New York: McGraw-Hill; 1980:113-119.
28. SAS Institute, Inc. Inc. SAS/STAT® Software: Changes and Enhancements Through Release 6.12. Cary, NC: SAS Institute; 1996.
29. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988:800-802.
30. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160: 533-540.
31. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240-249.
32. Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1999;175:120-126.
33. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152:1368-1371.
34. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol. 1997;17:255-260.